Abel Hall LLC’s Corcept Therapeutics CORT Stock Holding History

Abel Hall LLC’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,082	Closed	-$238K	–	298
2025 Q1	$238K	Buy	+2,082	New	+$127K	0.14%	136

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Abel Hall LLC's CORT Position: Q2 2025 in Review

Abel Hall LLC sold out of Corcept Therapeutics (CORT) in Q2 2025, closing a stake of 2,082 shares — an estimated $238K sold.

Abel Hall LLC first reported a position in CORT in Q1 2025 and held it in 1 quarter. The position peaked at $238K in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2025.

Abel Hall LLC reported no remaining Corcept Therapeutics position as of Q2 2025 after selling out during the quarter.
Abel Hall LLC sold 2,082 Corcept Therapeutics shares in Q2 2025, an estimated $238K.
Abel Hall LLC first reported a position in Corcept Therapeutics in Q1 2025 and held it in 1 quarter.
Abel Hall LLC's Corcept Therapeutics position peaked at $238K in Q1 2025.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2025.

Based on Abel Hall LLC's 13F filing for Q2 2025, filed 23 Jul 2025.